This transcription factor is a druggable target that has been evaluated in melanoma [68] and ovarian cancer [69], as well as in TP53 and RB1 defective tumors [70], and its downregulation has shown anti-tumor properties in colorectal cancer [71]. Here, RB1 is linked to ovarian carcinoma.